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The anti-CD20 chimaeric monoclonal antibody Rituxi-
mab has recently been shown to induce signiﬁcant clinical
response in a proportion of patients with refractory
chronic graft-versus-host disease (cGVHD). We now
report 38 patients, median age 48 years (22–61), receiving
Rituximab for refractory cGVHD, assessed for clinical
response and survival. Median duration of cGVHD before
Rituximab was 23 months (range 2–116), the median
number of failed treatment lines was 3 (range 1 to X6)
and the median follow-up after Rituximab was 11 months
(1–88). Overall response rate was 65%: skin 17/20
(63%), mouth 10/21 (48%), eyes 6/14 (43%), liver 3/12
(25%), lung 3/8 (37.5%), joints 4/5, gut 3/4, thrombo-
cytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and,
myasthenia gravis 1/1. During the study period 8/38 died:
causes of death were cGVHD progression (n¼ 3), disease
relapse (n¼ 1), infection (n¼ 3), sudden death (n¼ 1). The
actuarial 2 year survival is currently 76%. We conﬁrm
that Rituximab is effective in over 50% of patients with
refractory cGVHD and may have a beneﬁcial impact on
survival.
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Introduction
Refractory chronic graft-versus-host disease (cGVHD) is
an intractable complication associated with considerable
morbidity and mortality: the average mortality is 26% and
there has been no improvement over the past two
decades.1–2 Intensiﬁcation of immunosuppressive therapy
has failed to show any beneﬁcial effect on survival.3 A new
therapeutic approach is therefore greatly needed.
Recently, the Boston group has reported encouraging
results with the anti-CD20 chimaeric monoclonal antibody
Rituximab;4 it is indeed possible that Rituximab may be
acting on the B-cell component of the disease. In keeping
with this observation is the increasing use of Rituximab in
the treatment of several autoimmune disorders such as
immune thrombocytopaenias,5 haemolytic anemia,6 rheu-
matoid arthritis,7 mixed cryoglobulinemia,8 systemic lupus
erythematousus 9 and thrombotic thrombocytopenic pur-
pura.10
To address this issue better, the GITMO (Italian Group
Bone Marrow Transplant) performed a retrospective study
concerning the use of Rituximab in patients with refractory
cGHVD. The results of this analysis are reported here.
Patients, materials and methods
This study was conducted retrospectively to established
GITMO transplant centre experience in the use of
Rituximab for the treatment of refractory cGVHD, that
is, cGHVD already treated and not responsive to one at
least prior treatment and/or necessitating chronic admin-
istrations of medium to high-dose steroids. Patient details,
time and type of transplant, time of cGVHD onset, organ
involvement, previous treatments, therapeutic schedule,
safety, response rate and response duration were investi-
gated.
Because the study was retrospective and multicentre, no
single study-speciﬁc consent form could be obtained.
However, each GITMO centre was asked to report the
data of only those patients with a documented consent in
their medical records.
To optimize collection and standardization of the results,
participating GITMO centres were required to report data
concerning clinical, functional, biochemical and radiologi-
cal appearances according to the different sites of organ
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involvement on speciﬁc predeﬁned data forms. One single
individual with recognized experience in haematopoietic
stem cell transplantation completed the response forms
for each centre. Skin and mucosa were approached by mean
of a clinical assessment, to establish the presence of rash,
scleroderma, lichenoid changes, xerostomia and any
modiﬁcation after therapy. The lachrymal apparatus was
investigated clinically and with the Shirmer test. Joint
involvement was studied analyzing level of subjective
discomfort and functional limitations. To assess the liver
we analysed the laboratory parameters (that is, bilirubin,
transaminases, cholestasis index). Data on thorax included
X-rays and high-resolution computed tomography scans
together with pulmonary function tests (forced expiratory
volume, vital capacity and diffusion capacity of carbon
monoxide), which were evaluated for patients with lung
involvement. Finally, for the gastrointestinal system, we
considered clinical symptoms (weight and diarrhoea,
vomiting). Analyzing all these variables, we deﬁned the
following response criteria: complete response (CR) in
cases of complete resolution of cGVHD manifestations in
the organ involved; partial response (PR) in cases of 50%
or more regression of cGVHD manifestations; no response
(NR) less than 50% organ improvement, or exacerbation
during or after therapy. Time to response (TTR) was
considered as the time elapsed between Rituximab admin-
istration and start of cGVHD improvement. The safety of
Rituximab was analyzed short and mid term.
Results
Data of 38 adult patients treated with Rituximab were
supplied by 12 GITMO centres accredited for allogeneic
stem cell transplantation. Main patient clinical character-
istics are summarized in Table 1. Most cases (29 of 38)
received a fully matched sibling transplant and only a
minority (9 of 38) a matched unrelated transplant; eight
patients received a nonmyeloablative conditioning regimen.
In two cases cGVHD followed the administration of donor
lymphocytes (DLI).
Thirty-one patients had an extensive form of cGVHD,
according to the revised Seattle classiﬁcation,11 and the
median time between cGVHD development and Rituximab
treatment was 23 months (range 2–116). Skin and mouth
were the two most frequent sites of cGVHD involvement,
affecting 28 and 23 patients, respectively (Table 2). Other
sites of organ involvement were eyes (16 patients), liver (14
patients), lung (nine patients), joints (six patients), gut (four
patients), vagina (two patients); four patients had haema-
tological manifestations (three immune thrombocyto-
paenia, one pure red cell aplasia (PRCA)) (Table 2); one
patient, previously described,12 had a very severe from of
myasthenia gravis.
Rituximab was offered as a second or further line of
therapy in 9 and 29 cases, respectively. The seven patients
with limited cGVHD had previously failed therapy either
with steroid and cyclosporine (ﬁve patients), steroid and
azathioprine (two patients), steroid, azathioprine, myco-
phenolate mofetil and photopheresis (one patient). During
the period of Rituximab administration, patients were
continued on baseline immunosuppressive therapy. In all
cases Rituximab was given intravenously at the conven-
tional dose of 375mg/m2 weekly; the median number of
administrations was 4 (range 1–20), with heterogeneity
caused by different clinical situations or institutional
therapeutic policies. In particular, eight patients received
up to 16 other infusions aimed at consolidation or
maintenance, besides the four weekly administrations. Six
of seven patients with limited cGVHD received four
infusions and one received three.
Rituximab resulted in active control of different cGVHD
manifestations in 65% of patients; results are reported in
Table 2. Brieﬂy, as far as skin involvement is concerned,
signiﬁcant improvement was observed in 63% of cases,
the majority (56%) reaching PR. Notably, treatment was
effective for sclerodermatous manifestations in 64% of
patients. Median TTR and response duration were 57 days
and 10 months, respectively; 6 of 17 responding patients
had skin cGVHD that recurred or worsened. A signiﬁcant
improvement was observed in 48% (19% CR and 29% PR)
of patients with mouth involvement, with a median TTR
and median response duration of 46 days and 11 months,
respectively; 1 of 10 patients who responded had mouth
cGVHD that worsened 7 months after Rituximab treat-
ment. For patients with skin and mouth cGVHD, the
therapeutic effect of Rituximab allowed the reduction of
baseline immunosuppressive therapy in 11 of 17 and 6 of 10
Table 1 Patients’ main clinical features
Patients 38
Median age, years (range) 48 (22–61)
Male/female 20/18
Diagnosis
Chronic myeloid leukaemia 8
Acute myeloid leukaemia 13
Acute lymphoblastic leukaemia 3
Multiple myeloma 6








Stem cell source: bone marrow/peripheral blood 12/26
cGVHD: limited/extensive 7/31
Median duration of cGvHD before Rituximab,
months (range)
23 (2–116)
Median number of failed treatment lines
before Rituximab (range)
3 (1–X6)
Previous treatments of cGVHD Patients
Prednisone 38








Median follow-up after Rituximab, months (range) 11 (1–88)
Abbreviation: cGVHD¼ chronic graft-versus-host disease.
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responding patients, respectively (Table 2). In particular,
the median dose reduction of steroid therapy was 82%
(range 0–100%; Table 2). With regard to the effect on liver,
lung and gut manifestations, the small number of cases
limited the analysis; however, the good results observed in
some patients suggest a potential effect of Rituximab in
controlling cGVHD in these organs too (Table 2). Simi-
larly, a signiﬁcant number of patients experienced clinical
and functional improvement of eye and joint manifesta-
tions of cGVHD (Table 2). Neither of the two patients with
vagina involvement, however, improved after Rituximab
treatment. Two of the three patients with immune
thrombocytopaenia responded (one CR and onc PR),
whereas the patient with PRCA was refractory. One patient
with refractory myasthenia gravis achieved complete
regression of neurological symptoms and disappearance
of the autoantibodies against acetyl-coline receptors,12 still
present after 84 months. Particularly for patients with skin,
mouth and eyes involvement, response to therapy appeared
to be related to grade of cGHVD (limited vs extensive) and
the number of Rituximab administrations (p4 vs 5–8 vs
48), but not with length of the interval between cGVHD
onset and Rituximab (p23 vs 423 months).
Short- and mid-term toxicity were characterized by the
development of grade I–II infusion-related symptoms in
four patients, renal failure, severe tremors and ischemic
stroke in one patient each. As for infectious complications,
we registered three cases of pneumonia and one case of
Gram-negative sepsis. Because of the development of these
adverse events, six patients interrupted the therapeutic
program before the fourth administration.
During the study period 8/38 died: causes of death were
cGVHD progression (n¼ 3, all related to progressive lung
cGVHD), disease relapse (n¼ 1), infections (n¼ 3; causa-
tive organisms not identiﬁed), sudden death (n¼ 1). The
actuarial 2 year survival is currently 76%.
Discussion
cGVHD is the most common nonrelapse complication after
allogeneic stem cell transplantation and affects 40–70% of
survivors beyond day 100. cGVHD is becoming a more
frequent problem due to increasing age of recipients, use of
alternative donors, use of peripheral blood stem cells as the
source of the graft, and increasing use of donor lymphocyte
infusions for the treatment of relapse. The pathophysiology
of cGVHD is poorly understood; our current under-
standing starts with pathogenic donor T cell, that expands
in response to allo- or autoantigens unchecked by normal
thymus or other peripheral mechanisms of abrogation.
These pathological T cells attack target tissues directly
through cytotoxic attack, secretion of inﬂammatory cyto-
kines, such as interleukin-b (IL-1b), tumour necrosis factor-
a (TNF-a), IL-6 and interferon-g (IFNg), or promotion of
B-cell activation and antibody production. Tissue damage
may eventually lead to ﬁbrosis and loss of function.
The mainstay of cGVHD treatment is a ciclosporin A
and prednisone regimen. Approximately 40% of patients
fail to respond to initial therapy. Patients with refractory
cGVHD are usually treated with several salvage therapies
mainly targeted at T-cells, such as mycophenolate mofetil,
sirolimus, daclizumab, thalidomide and alemtuzumab or at
cytokines, such as anti-TNF-alpha monoclonal antibodies.
There has recently been an emerging interest in the
pathological effect of B cells in auto- and alloimmune
Table 2 Results after treatment with Rituximab according to the different site of cGVHD involvement
Organ
involvement
















Skin 28 1 17 (63%) 2 (7%) 10 (37%) 11/17 Evaluable pts: 10;
DR: 82% (0–100)
57 (7–150) 10 (1–22) 12 (1–33) 6/17
Scleroderma 11 0 7 (64%) 0 4 (36%)
Mouth 23 2 10 (48%) 4 (19%) 11 (52%) 6/10 Evaluable pts: 6;
DR: 82% (25–100)
46 (7–210) 11 (1–84) 13 (2–84) 1/10
Eyes 16 2 6 (43%) 2 (14%) 8 (57%) 2/6 Evaluable pts: 3;
DR: 100% (all pts)
138 (7–270) 12 (9–70) 14 (10–22) 0
Liver 14 2 3 (25%) 0 9 (75%) 0/3 Evaluable pts: 2;
DR: 25% and 90%
49 (43–56) 13 (12–18) 16 (1–18) 0
Lung 9 1 3 (37.5%) 0 5 (63%) 3/3 Evaluable pts: 2;
DR: 76% and 100%
60 (50–120) 12 (7–15) 15 (12–22) 0
Joints 6 1 4 (80%) 0 1 (20%) 2/4 Evaluable pts: 4;
DR: 100% (76–100)
78 (22–210) 17 (12–22) 17 (12–22) 0
Gut 4 0 3 (75%) 0 1 (25%) 0/3 Evaluable pts: 2;
DR: 0% and 100%
NA NA NA NA
Vagina 2 0 0 0 2 / / / / / /
Thrombo-
cytopaenia
3 0 2 (66%) 1 (33%) 1 (33%) 2/2 NA NA NA NA NA
PRCA 1 0 0 0 1 / / / / / /
Myasthenia
gravis
1 0 1 1 0 1/1 Evaluable pts: 1 DR:
100%
30 84 84 0
Abbreviations: cGVHD¼ chronic graft-versus-host disease; CR¼ complete response; DR-IS¼ dose reduction of immunosuppressive therapy after
Rituximab. The modiﬁcation of previous baseline immunosuppressive therapy after Rituximab is here reported; DR-steroid¼ for patients in treatment with
steroid, the percentage dose reduction is indicated; NA¼ data not available; NR¼ no response; NV¼ not valuable; OR¼ overall response; PRCA¼pure
red cell aplasia; Pts¼patients; RD¼ response duration; follow-up¼median follow-up from Rituximab treatment (range); TTR¼ time to response.
Rituximab in cGVHD
F Zaja et al
275
Bone Marrow Transplantation
reactivity. B cells may have a primary direct and/or indirect
role in the pathogenesis of several immune-mediated
diseases by means of autoantibodies or cytokine produc-
tion, interaction with T cells and acting as antigen-
presenting cells. In cGVHD, the status of the B-cell
compartment appears somewhat paradoxical. Patients with
cGVHD may show severe B-lymphocytopaenia and B-cell
hyperactivity at the same time, as documented by the
production pathological antibodies.13–14
On the basis of such considerations and with the good
results observed in the treatment of several autoimmune
diseases,5–10 Rituximab has been investigated in a small
number of patients with refractory cGVHD using the
standard regimen of 375mg/m2/week for 4 weeks.4,15–17
Ratanatharathorn et al.15 documented a sustained response
in four of eight patients with steroid-refractory cGVHD
with diffuse or localized sclerodermoid manifestations.
Similarly, Canninga-vanDijk et al.16 and Okamoto et al.17
observed cases with clinical, laboratory and histo-
logical improvement after Rituximab treatment. Recently,
Cutler et al.4 reported the results of their phase I–II
study with Rituximab in 21 patients with steroid-refractory
cGVHD. Treatment was well tolerated, and toxicity
limited to infectious events, without any haemato-
logical toxicities and only a signiﬁcant reduction
in circulating immunoglobulins documented after therapy.
Objective responses were documented in 70% of patients
(including 10% complete response) primarily for those
with skin and musculoskeletal involvement, allowing
tapering, and in some cases withdrawing, of previous
immunosuppressant therapy. A correlation between
clinical response and decrease in the titre of antibodies
against Y chromosome-encoded minor HLA antigens
was shown.
The results of these preliminary studies highlight the
potential therapeutic activity of Rituximab on some
cGVHD manifestations and a particularly high efﬁcacy
for skin involvement, including scleroderma. Systemic
sclerosis, which shares some clinical aspects with scler-
odermoid cGVHD, is characterized by altered B-cell
homeostasis with hyper-gammaglobulinemia, polyclonal
and memory B-cell hyperactivity and production of speciﬁc
autoantibodies.18–19 In this disease B-cell hyperactivity
could be not only an epiphenomenon of T-activation but
also the expression of a primary pathogenic activity in the
development of ﬁbrosis. This primary pathogenic role of B
cells appears further emphasised by recent data showing the
beneﬁcial therapeutic effect of B-cell depletion in a
preclinical mouse model.20
Our study conﬁrms the activity of Rituximab in
refractory cGVHD in a larger series of patients. Treatment
was generally well tolerated and nearly 60 and 50% of
patients had a clinical improvement of their skin and
mouth manifestations, respectively. The median TTR was
nearly 2 months and in some cases responses were durable.
Responses were also detectable in some patients with eye,
liver, lung, gut and joint involvement, allowing reduction
and/or suspension of previous baseline immunosuppressive
therapy in a signiﬁcant number of patients. It should be
noted that response appeared to be related to the duration
of treatment and extent of cGVHD.
We are aware of the limitations of this retrospective
multicentre study: the number of Rituximab administra-
tions varied according to the individual institutional
therapeutic policy; collection of objective clinical results
may have had some limitations in some patients; further-
more, we are unable to collect sufﬁcient biological data to
evaluate immunological changes after treatment and the
possible relationship between clinical and laboratory
modiﬁcations. However, our results are in line with
previously reported studies, and support a real therapeutic
activity of Rituximab for the treatment of patients with
cGVHD.
In conclusion, these data indicate that Rituximab may
reduce multiorgan involvement of some cGVHD manifes-
tations and stimulate conﬁrmation through prospective
controlled studies in more homogeneous groups of patients
should be sought. Similar to that already observed in
some autoimmune disorders, the beneﬁcial effect of B-cell
depletion highlights the potential primary pathologic role
of B lymphocytes in the development of cGVHD. A better
understanding of the immune-biologic mechanisms that
regulate this disorder will be of assistance.
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